Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite™ assay) – Benefit for Stratification of Multiple Myeloma?
Authors:
V. Ščudla 1; P. Lochaman 2; T. Pika 3; J. Zapletalová 4; J. Minařík 3; J. Bačovský 3
Authors place of work:
III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
1; Oddělení klinické biochemie, FN Olomouc
2; Hemato‑ onkologická klinika LF UP a FN Olomouc
3; Ústav lékařské biofyziky, LF UP v Olomouci
4
Published in the journal:
Klin Onkol 2015; 28(5): 359-369
Category:
Original Articles
doi:
https://doi.org/10.14735/amko2015359
Summary
Background:
The aim of the study was the comparison of two novel stratification models in multiple myeloma (MM), ie. according to Avet‑ Loiseau (A‑ L) and according to Ludwig (L), based on the HLC‑ r index (ratio of serum levels of involved‑ HLC/ uninvolved‑ HLC, ie. HLC‑ κ/ HLC‑ λ assessed using ie. nephelometric/turbidimetric technique using specific polyclonal antibodies on a Binding Site SPAPLUS) technique) and β2‑ microglobulin (β2‑ M) with selected prognostic factors (PF) of MM and staging systems according to Durie‑ Salmon (D‑ S) and International Staging System (ISS).
Patients and Methods:
In a cohort of 132 patients (94 with IgG and 38 with IgA type of MM) at the time of diagnosis, we assessed HLC‑ r, selected PF and D‑ S, ISS, A‑ L and L stratification systems.
Results:
Unlike in IgA isotype, in IgG isotype we found a significant relationship of HLC‑ r to stratification according to D‑ S and ISS with the difference between A and B substages according to D‑ S (p = 0.049) and between ISS stages 1 vs. 3 (p = 0.001). In the IgG group, there was highly significant relationship of the depth of Hb and albumin decrease and β2‑ M increase to the results of stratification according to ISS, A‑ L and L model (p < 0.0001), increase of LDH in the ISS system and A‑ L, and creatinine according to ISS and L but not the relationship of the stages according to any of the stratification systems to the values of FLC‑ r (ratio of serum free light chains κ/ λ of immunoglobulin), thrombocytes and Ca. In the IgA type, there was a significant relationship of the depth of the decrease of Hb, thrombocytes, albumin and increase of β2‑ M to the results of stratification according to ISS, A‑ L and L and increase of creatinine in the case of ISS, but not of the values of FLC‑ r, Ca and LDH in the case of any of the stratification systems. The degree of correlation of selected PF, especially of Hb, albumin and β2‑ M, event. of thrombocytes, LDH and creatinine to the stages according to ISS and to stage 1–3 according to A‑ L and L model was in IgG vs IgA isotype significantly different (p < 0.0001– 0.030). Staging system according to ISS had proportional distribution of stages 1– 3, whereas in the A‑ L model prevailed in IgA and IgG isotype risk category 2, ie. intermediate-risk (47.3 and 44.7%) and in the L model prevailed risk category 3, ie. high‑risk (41.5 and 52.6%) with low count of category 1, ie. low‑ risk category (23.4 and 10.5%). McNemar‑ Bowker test of symmetry showed in both types of MM the highest concordance between the stratification according to D‑ S and L in category 3, ie. high‑risk (31.9 vs. 28.9%) with overall accord only in 53.2 and 42.1% and with significant shift in the case of IgG isotype only (p = 0.036). In IgG and IgA isotype there was an overall concordance in the distribution of categories 1– 3 according to ISS vs. A‑ L (62.4 and 63.2%) but with significant shift of the stratification (p = 0.002 and 0.028). In the case of IgG and IgA isotype there was a close relationship between the models A‑ L and L (64.5 and 81.6%) with significant stratification shift (p < 0.0001 and 0.030).
Conclusion:
The new stratification models for MM according to A‑ L and L are easily practically applicable, with close relationship to principal PF but they need separate assessment of IgG and IgA isotypes of MM. The choice of optimal model for routine practice needs a validation study aimed at progression free survival and overall survival.
Key words:
multiple myeloma – immunoglobulin – free light chain – heavy/light chain – prognosis – stratification
This study was supported by Internal Grant Agency of the Czech Ministry of Health NT/12451-5.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
16. 6. 2015
Accepted:
25. 6. 2015
Zdroje
1. Rajkumar SV, Dimopoulos MA, Palumbo A et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15(12): e538– e548. doi: 10.1016/ S1470‑ 2045(14)70442‑ 5.
2. Hajek R, Adam Z, Scudla V et al. Guidelines of Czech Myeloma Group 2012: diagnosis and treatment of multiple myeloma. Transf Hematol 2012; 18: 5– 89.
3. Bradwell AR. Analysis of immunoglobulin heavy chain/ light chain pairs (HevyliteTM). In: Bradwell AR (ed.). Serum free light chain analysis (plus Hevylite). 6th ed. Birmingham: the Binding Site Ltd 2010: 301– 320.
4. Bradwell AR, Harding SJ, Fourrier NJ et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/ λ ratios. Clin Chem 2009; 55(9): 1646– 1655. doi: 10.1373/ clinchem.2009.123828.
5. Keren DF. Heavy/ light‑chain analysis of monoclonal gammopathies. Clin Chem 2009; 55(9): 1606– 1608.
6. Katzmann JA, Kyle RA, Benson J et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55(8): 1517– 1522. doi: 10.1373/ clinchem.2009.126664.
7. Koulieris E, Panayiotidis P, Harding SJ et al. Ratio of involved/ unilvolved immunoglobulin quantification by HevyliteTM assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol 2012; 1: 9. Available from: http:/ / www.enhoonline.org/ content/ 1/ 1/ 9.
8. The Binding Site Group Ltd. Practical consideration of Hevylite immunoassays. In: The Binding Site Group Ltd. Serum free light chain analysis plus Hevylite. 7th ed. Birmingham: the Binding Site Ltd 2015: 95– 121.
9. Vavrova J. Assessment of free light chains and HevyliteTM in monoclonal gammopathies. In: Maisnar V, Tichy M (eds). Monoclonal immunoglobulins – occurrence, significance and possibilities of their detection. 1st ed. Praha: Nucleus Hradec Kralove 2012: 55– 60.
10. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121(5): 749– 757.
11. Bergsagel PL, Kuehl WM, Zhan F et al. Cyclin D dysregulation: an early and unifying pathogenetic event in multiple myeloma. Blood 2005; 106(1): 296– 303.
12. Shaughessy JD Jr, Zhan F, Burington BE et al. A validated gene expression model of high‑risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109(6): 2276– 2284.
13. Avet‑ Loiseau H, Harousseau JL, Moreau P et al. Heavy/ light chain specific immunoglobulin ratios at presentation are prognostic for progression free survival in the IFM 2005– 01 myeloma trial. Blood 2009; 114: 722: abstr. 1818.
14. Avet‑ Loiseau H, Mirbahai L,Harousseau JL et al. Serum immunoglobulin heavy/ light chain ratios are independent risk factors for predict progression free survival in multiple myeloma. Haematologica 2010; 95: 395.
15. Ludwig H, Milosavljevic D, Zojer N et al. Immunoglobulin heavy/ light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013; 27(1): 213– 219. doi: 10.1038/ leu.2012.197.
16. Bradwell AR, Harding S, Fourrier N et al. Prognostic utility of intact immunoglobulin Ig’kappa/ Ig’lambda ratios in multiple myeloma patients. Leukemia 2013; 27(1): 202– 207. doi: 10.1038/ leu.2012.159.
17. Ščudla V, Lochman P, Pika T et al. Analýza vztahu párů těžkých/ lehkých řetězců imunoglobulinu (HevyliteTM) k výsledkům gelové elektroforézy a nefelometrickému vyšetření proteinů séra při diagnóze mnohočetného myelomu. Čas Lék Čes. In press 2015.
18. Scudla V, Lochman P, Pika T et al. Differences in relationship between immunoglobulin heavy/ light chain pairs (HevyliteTM) and selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma. Biomedical Papers. In press 2015.
19. Ludwig H, Milosavljevic D, Zojer N et al. Supression of the non‑involved HLC pair correlates with survival in newly diagnosed and relapsed/ refractory patients with myeloma. Congres of European Haematology Association, Milano 2014: abstr. 980.
20. Katzmann JA, Rajkumar SV. A windows into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains. Leukemia 2013; 27(1): 1– 2. doi: 10.1038/ leu.2012.201.
21. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23(15): 3412– 3420.
22. Alexanian R. Blood volume in monoclonal gammopathy. Blood 1997; 49(2): 301– 307.
23. Kim J, Hayton WL, Robinson JM et al. Kinetics of FcRn‑ mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism‑based model. Clin Immunol 2007; 122(2): 146– 155.
24. Akilesh S, Christianson GJ, Roopenian DC et al. Neonatal FcR expression in bone marrow‑ derived cell functions to protect serum IgG from catabolism. J Immunol 2007; 179(7): 4580– 4588.
25. Anderson CL, Chandhury C, Kim J et al. Perspective FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006; 27(7): 343– 348.
26. Chandhury C, Brooks C, Carter D et al. Albumin binding to FcRn: distinct from the FcRn‑ IgG interaction. Biochemistry 2006; 45(15): 4983– 4990.
27. Pika T, Hermanova Z, Lochman P et al. System HevyLiteTM and IgA monoclonal gammopathy – first experience. Klin Biochem Metab 2011; 19: 86– 91.
28. Katzmann JA, Clark R, Kyle RA et al. Supression of uninvolved immunoglobulins defined by heavy/ light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013; 27(1): 208– 212. doi: 10.1038/ leu.2012.189.
29. Murillo‑ Florez I, Andrade‑ Campos M, Montes‑ Limon A et al. Predictive value of light and heavy chain analysis in multiple myeloma patients treated with bortezomib. Haematologica 2013; 98: 1519a.
30. Koulieris E, Maltezas D, Eytychia N et al. Impact of novel M‑ component based biomarkers on to progression free survival after treatment in intact immunoglobulin multiple myeloma. Blood 2012; 120: 121.
31. Ludwig H, Faint J, Zojer N et al. Serum heavy/ light chain and free light chain measurements provide prognostic informatic, alow creation of a prognostic model and identify clonal changes (clonal tiding) through the course of multiple myeloma. Blood 2011; 118: 1244.
32. Avet‑ Loiseau H, Mirbahai L, Mathiot C et al. Nephelometric assays Ig’kappa and Ig’lambda used for diagnosing and monitoring multiple myeloma. Haematologica 2011; 96: 393a.
33. Kraj M. Immunoglobulin heavy chain/ light chain pairs (HLC, HevyliteTM) assays for diagnosing and monitoring monoclonal gammopathies. Adv Clin Exp Med 2014; 23(1): 127– 133.
34. Koulieris MW, Kyrtsonis MC, Maltezas D et al. Quantification of serum IgM‑ kappa and IgM‑ lambda in patients with Waldenströms macroglobulinemia (WM) at diagnosis and during disease course. Clinical correlations. Blood 2010; 1116: 1238.
35. Leleu X, Koulieris E, Maltezas D et al. Novel M‑ component based biomarkers in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11(1): 164– 167. doi: 10.3816/ CLML.2011.n.039.
36. Lakomy D, Lemaire‑Ewing S, Denimal D et al. Evaluation of the new Hevylite TM IgA assay for the diagnosis and follow‑up of monoclonal gammopathies. Ann Biol Clin 2013; 71(2): 157– 163. doi: 10.1684/ abc.2013.0805.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2015 Číslo 5
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Methods of Assesing Quality of Life in Women with Breast Cancer – Overview and Basic Characteristics
- Surgical Treatment of Lung Metastases of Colorectal Carcinoma – Survival and Prognostic Factors
- Forbidden to Drive – a New Chemotherapy Side Effect
- Combining Systemic Therapies with Radiation in Non‑ small Cell Lung Cancer